Combination treatment for HER2-positive cancers and resistant ovarian cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two drugs, DS-8201a and olaparib, for people with cancers that have a protein called HER2, and for those with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced cancer that has not responded to standard treatments, or ovarian cancer that has stopped responding to platinum chemotherapy.
- Your tumor must have a certain level of HER2 protein or gene changes, confirmed by a lab test.
- You must have had at least one previous line of chemotherapy, but you can have had many more.
- You must be 18 years or older and have a good performance status (able to care for yourself).
- You need to have a tumor sample (biopsy or archival tissue) available for testing.
- Your organ function (blood counts, liver, kidneys, heart) must be within acceptable limits.
- You must not have had certain treatments recently (like chemotherapy, radiation, or surgery) within 4 weeks, and no active lung disease or severe heart problems.
- If you are of childbearing potential, you must agree to use highly effective contraception during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, trastuzumab deruxtecan and azenosertib, for people with stomach cancer or other solid tumors that have a specific protein called HER2. It aims to see if this combination can help when other treatments have stopped working.
This trial tests the safety of combining two drugs, CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd), in people with HER2-positive solid tumors or certain types of breast cancer. If you have advanced cancer that hasn't responded to other treatments, this study may be an option.
This study tests a new drug combination (QL1706 plus olaparib) for people with HER2-negative breast cancer that has progressed after earlier treatments. It aims to see if this combo can help shrink tumors or slow the cancer when the tumor has a specific DNA repair deficiency.
This trial tests a new drug combination (trastuzumab rezetecan plus carboplatin) with or without bevacizumab, compared to standard chemotherapy, for ovarian cancer that has come back after platinum-based treatment. It aims to see if this combination works better than the usual options.
This trial tests a combination of two targeted drugs for advanced or recurrent ovarian cancer in people who do not have a BRCA gene change. The goal is to see if the combination can shrink tumors or slow the disease.
This trial tests two drugs, idetrexed and olaparib, in people with a type of ovarian cancer that has stopped responding to standard treatments. It aims to see if this combination can help shrink or control the cancer.
Hear when a new Metastatic Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.